Journey Medical Reports Q1 Loss Narrowing From $0.18, Revenue Tops Forecasts
Journey Medical Corporation posted a Q1 net loss of $0.08 per share, down from a $0.18 loss a year earlier, while revenue outpaced analyst forecasts. Management highlighted year-over-year sales growth in core dermatology products and outlined supply-chain optimizations and marketing initiatives.
1. Q1 Financial Results
Journey Medical recorded a first-quarter net loss of $0.08 per share, an improvement from a $0.18 loss in the same period last year. The results came alongside revenue that exceeded analyst expectations, despite the continued investment in R&D and marketing.
2. Revenue Growth Drivers
Management pointed to stronger demand across its specialty dermatology portfolio as the primary factor behind revenue growth. Growth was supported by increased prescription volumes and expanded coverage with key pharmacy benefit managers.
3. Strategic Initiatives
Executives detailed plans to optimize the supply chain through vendor consolidation and manufacturing efficiencies. The company also emphasized ramping up direct‐to‐consumer marketing campaigns to bolster brand awareness and support long-term sales momentum.